Novo Nordisk's Downgraded Expectations - What The Market Is (Obviously) Missing

Group 1 - Novo Nordisk A/S (NVO) has previewed its Q2 sales and operating profit growth in a recent press release [1] - The company has downgraded its full-year 2025 guidance [1] - The investing group Haggerston BioHealth provides insights into biotech, pharma, and healthcare industries, including sales forecasts and financial analyses [1]